You are here

Article Text

Article menu

Download PDFPDF

Poster session 1: Autoantibodies, biomarkers and imaging (1)
PS1:8 Anti-ro false-negatives detection through anti-ro52 kda and anti-ro60 kda analysis in systemic lupus erythematous patients
Free
  1. E Grau1,
  2. I Chalmeta Verdejo1,
  3. E Labrador Sanchez1,
  4. M Fernandez Matilla2,
  5. FM Ortiz Sanjuan1,
  6. CM Feced Olmos1,
  7. N Fernadez-Llanio Cornella2,
  8. K Arevalo Ruales1,
  9. R Negueroles Albuixech1,
  10. J Ivorra Cortes1,
  11. JJ Fragio Gil1,
  12. I Martinez Cordellat1,
  13. R Gonzalez Mazario1,
  14. L Gonzalez Puig1,
  15. C Alcañiz Escandell1,
  16. C Najera Herranz1,
  17. I Canovas Olmos1,
  18. E Vicens Bernabeu1,
  19. JE Oller Rodriguez1,
  20. M de la Rubia Navarro1,
  21. JA Castellano Cuesta2,
  22. V Fornes Ferrer3,
  23. D Hervas Marin3,
  24. D Gimenez-Romero4 and
  25. JA Roman Ivorra1
  1. 1Rheumatology Department. HUP La Fe, Valencia, Spain
  2. 2Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain
  3. 3Biostatistics Unit. IIS La Fe, Valencia, Spain
  4. 4Physical-Chemistry Department, UV, Valencia, Spain

Abstract

Purpose The aim of the present study is to identify false-negatives for anti-Ro by analysing both 52 KDa and 60 KDa subunits separately, as well as to characterise if there are clinical or molecular differences in this subgroup of patients compared to anti-Ro negative cases.

Methods A cross-sectional, observational study of patients diagnosed of SLE according to SLICC 2012 criteria was performed. In these patients a complete blood-test was made, and clinical data by personal interview was collected. INF1A, Anti-Ro, anti-Ro52KDa and anti-Ro60KDa levels where measured by colorimetric methods. Biostatistical analysis was performed with R 3.3.2.

Results We selected 69 SLE patients with negative results for anti-Ro (2.34±4.17 U/mL) out of 142 total SLE patients. A total of 51 patients were negative for both anti-Ro subunits and 18 cases presented positive results (up to 20 pg/mL) for at least one of them (See table 1).

The subgroup of patients that exhibit simultaneously high levels of anti-Ro52KDa and anti-Ro60KDa have higher clinical activity compared to negative anti-Ro cases (75% of active patients against 41.2% in anti-Ro negative patients). However, no differences in the accumulated damage evaluated by SLICC score between negative anti-Ro cases and patients with at least one positive subunit were observed.

We analyse serum levels of INF1A cytokine in the four groups of patients, and anti-Ro and subunits negative cases showed significant lower INF1A levels than the other patients (8.26±14.87 pg/mL and 26.62±40.71 pg/mL respectively; p=0.04). In addition, patients with high levels of anti-Ro52KDa subunit are those with the highest INF1A levels (anti-Ro 52+/anti-Ro60- 23.5±47.6 pg/mL of INF1A; anti-Ro 52+/anti-Ro60 +36.4 ±37.9 pg/mL of INF1A).

Conclusion In our anti-Ro seronegative patients, a 26% of false-negative cases were detected. These cases with high levels of almost one anti-Ro subunit showed significantly higher levels of INF1A in contrast to negative cases, supporting the fact that they are indeed a different group from the negative cases. Moreover, the high INF1A levels could be the reason of the observed differences in the clinical activity measured by SLEDAI score in both groups.

View this table:
Abstract PS1:8 Table 1
  • Anti-Ro

https://doi.org/10.1136/lupus-2018-abstract.57

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.